Antiplatelet Therapy for Acute Ischemic Stroke Patients With Thrombocytopenia
Overview
- Phase
- Not Applicable
- Intervention
- aspirin, clopidogrel, cilostazol, and dipyridamole
- Conditions
- Acute Ischemic Stroke
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Enrollment
- 1200
- Locations
- 1
- Primary Endpoint
- 90-day Composite events
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.
Detailed Description
Antiplatelet therapy is widely used in non-cardiogenic AIS patients for secondary prevention. However, it may also increase the risk of bleeding complications, especially in patients with thrombocytopenia. The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \> 18 years old
- •Acute ischemic stroke or transient ischemic attack with onset \< 7 days
- •The last blood routine test before enrollment indicates platelet count \< 100 x 10\^9 and \> 30 x 10\^9
Exclusion Criteria
- •Chronic renal dysfunction (GFR \< 30ml/min) or severe hepatic injury
- •Indications for anticoagulation therapy, e.g. atrial fibrillation
- •Myocardial infarction within 6 months before enrollment or received percutaneous coronary intervention in the past
- •Have or plan to receive CEA or CAS in the following 3 months
- •Life expectancy less than 1 year
- •Plan to receive invasive surgery in the following 3 months and have high risk of uncontrollable bleeding
- •Pregnant or lactating women
- •Individuals identified by researchers as unsuitable for participation in the study due to other reasons.
Arms & Interventions
Intervention
Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
Intervention: aspirin, clopidogrel, cilostazol, and dipyridamole
Outcomes
Primary Outcomes
90-day Composite events
Time Frame: 90 days
Composite events including ischemic stroke, hemorrhagic stroke, myocardial infarction, major extracranial hemorrhage, and vascular death within 90 days after enrollment
Secondary Outcomes
- 90-day myocardial infarction(90 days)
- 90-day non-major bleeding(90 days)
- 90-day ischemic stroke(90 days)
- 90-day all-cause death(90 days)
- 90-day hemorrhagic stroke(90 days)
- 90-day major extracranial hemorrhage(90 days)
- 90-day vascular death(90 days)
- Discharge mRS(Through hospitalization, an average of 7 days)